Neurogene (NASDAQ:NGNE – Get Free Report) and Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.
Insider and Institutional Ownership
52.4% of Neurogene shares are owned by institutional investors. 9.9% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Neurogene and Rapport Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neurogene | N/A | -32.81% | -27.96% |
| Rapport Therapeutics | N/A | N/A | N/A |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neurogene | 0 | 0 | 7 | 1 | 3.13 |
| Rapport Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
Neurogene currently has a consensus price target of $60.80, suggesting a potential upside of 346.66%. Rapport Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 241.13%. Given Neurogene’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Neurogene is more favorable than Rapport Therapeutics.
Valuation and Earnings
This table compares Neurogene and Rapport Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neurogene | $925,000.00 | 218.60 | -$36.32 million | N/A | N/A |
| Rapport Therapeutics | N/A | N/A | -$34.79 million | ($13.84) | -0.74 |
Rapport Therapeutics has lower revenue, but higher earnings than Neurogene.
Summary
Neurogene beats Rapport Therapeutics on 7 of the 10 factors compared between the two stocks.
About Neurogene
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
About Rapport Therapeutics
Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.
Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.
